433 related articles for article (PubMed ID: 33280422)
1. Eptinezumab for the preventive treatment of migraine.
Villar-Martínez MD; Moreno-Ajona D; Goadsby PJ
Pain Manag; 2021 Mar; 11(2):113-121. PubMed ID: 33280422
[TBL] [Abstract][Full Text] [Related]
2. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
Chiang CC; Schwedt TJ
Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
[TBL] [Abstract][Full Text] [Related]
3. Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of Migraine.
Pederson S; Biondi DM; Allan B; Cady R; Schaeffler B; Baker B; Latham J
Front Immunol; 2021; 12():765822. PubMed ID: 34759933
[TBL] [Abstract][Full Text] [Related]
4. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
[TBL] [Abstract][Full Text] [Related]
5. Galcanezumab for the prevention of migraine.
Frerichs LM; Friedman DI
Pain Manag; 2021 Mar; 11(2):101-112. PubMed ID: 33291980
[TBL] [Abstract][Full Text] [Related]
6. Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today?
Nagaraj K; Vandenbussche N; Goadsby PJ
Neurol India; 2021; 69(Supplement):S59-S66. PubMed ID: 34003149
[TBL] [Abstract][Full Text] [Related]
7. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update.
Charles AC; Digre KB; Goadsby PJ; Robbins MS; Hershey A;
Headache; 2024 Apr; 64(4):333-341. PubMed ID: 38466028
[TBL] [Abstract][Full Text] [Related]
8. Eptinezumab: First Approval.
Dhillon S
Drugs; 2020 May; 80(7):733-739. PubMed ID: 32266704
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and tolerability of eptinezumab in treating patients with migraine resistant to conventional preventive medications and CGRP (receptor) antibodies: a multicentre retrospective real-world analysis from Germany.
Scheffler A; Wenzel P; Bendig M; Gendolla A; Basten J; Kleinschnitz C; Nsaka M; Lindner D; Naegel S; Burow P; Fleischmann R; Holle D
J Headache Pain; 2024 May; 25(1):79. PubMed ID: 38755541
[TBL] [Abstract][Full Text] [Related]
10. Eptinezumab for the treatment of migraine.
Spuntarelli V; Negro A; Luciani M; Bentivegna E; Martelletti P
Expert Opin Biol Ther; 2021 Aug; 21(8):999-1011. PubMed ID: 34009094
[TBL] [Abstract][Full Text] [Related]
11. Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial.
Dodick DW; Lipton RB; Silberstein S; Goadsby PJ; Biondi D; Hirman J; Cady R; Smith J
Cephalalgia; 2019 Aug; 39(9):1075-1085. PubMed ID: 31234642
[TBL] [Abstract][Full Text] [Related]
12. Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study.
Alex A; Vaughn C; Rayhill M
Headache; 2020 Nov; 60(10):2454-2462. PubMed ID: 32969035
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of eptinezumab as preventive treatment for episodic/chronic migraine: A systematic review and meta-analysis.
Siahaan YMT; Hartoyo V; Hariyanto TI
Clin Exp Pharmacol Physiol; 2022 Nov; 49(11):1156-1168. PubMed ID: 35781694
[TBL] [Abstract][Full Text] [Related]
14. Eptinezumab for the treatment of migraine.
Scuteri D; Corasaniti MT; Tonin P; Bagetta G
Drugs Today (Barc); 2019 Nov; 55(11):695-703. PubMed ID: 31840684
[TBL] [Abstract][Full Text] [Related]
15. Migraine therapeutics differentially modulate the CGRP pathway.
Bhakta M; Vuong T; Taura T; Wilson DS; Stratton JR; Mackenzie KD
Cephalalgia; 2021 Apr; 41(5):499-514. PubMed ID: 33626922
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
[TBL] [Abstract][Full Text] [Related]
17. Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing.
Dodick DW; Gottschalk C; Cady R; Hirman J; Smith J; Snapinn S
Headache; 2020 Nov; 60(10):2220-2231. PubMed ID: 33165938
[TBL] [Abstract][Full Text] [Related]
18. [Novel migraine treatment with CGRP-related monoclonal antibodies].
Shibata M
Rinsho Shinkeigaku; 2020 Oct; 60(10):668-676. PubMed ID: 32893246
[TBL] [Abstract][Full Text] [Related]
19. Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study.
Smith TR; Janelidze M; Chakhava G; Cady R; Hirman J; Allan B; Pederson S; Smith J; Schaeffler B
Clin Ther; 2020 Dec; 42(12):2254-2265.e3. PubMed ID: 33250209
[TBL] [Abstract][Full Text] [Related]
20. Calcitonin-gene-related peptide pathway mAbs and migraine prevention.
Paemeleire K; MaassenVanDenBrink A
Curr Opin Neurol; 2018 Jun; 31(3):274-280. PubMed ID: 29432219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
